Standard BioTools, Inc. (LAB)
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
$0.69+1.72%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
QuarterlyIQ Insights · LAB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -48.3% |
| Our one-year growth estimate | diamond | -2.2% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 46.0 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 9 industry peers · Company calendar date is not available
LAB — earnings miss
Dated 2026-08-05
Results of Operations and Financial Condition On August 5, 2026, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three and six months ended June 30, 2026. The press release is attached hereto as Exhibit 99.1. The information set forth in the press release, except for the information set forth under the headings “Full Year 2026 Revenue Outlook” and “About Standard BioTools Inc.”, together with the forward-looking statem…
Why it matters: Fixing the delisting issue is key. It helps keep investor trust and market access.
Worry ifStandard BioTools meets the minimum bid price requirement set by Nasdaq.
Less concerning ifThe company does not meet Nasdaq listing rules. This leads to delisting.
Why it matters: The sale is part of the strategy to streamline operations and maximize value. Its success could impact cash flow.
Supportive ifThe sale closes successfully. This keeps the Mass Cytometry product lines running.
Worry ifThe sale fails to close by the end of 2026 due to regulatory or other issues.
Why it matters: The revenue guidance shows the company can grow and run its business well.
Supportive ifThe company reports full-year revenue in the range of $80 million to $85 million.
Worry ifRevenue is much lower than the guidance range.
Why it matters: Revenue guidance affects what investors expect. It was recently taken back.
Watch forNew revenue guidance for 2026 shows a good outlook.
Also watch forNo revenue guidance is given, or the guidance is still negative.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$256 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $641 loss on $10,000 · 6.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,179 loss on $10,000 · 61.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Meeting revenue expectations supports the company's guidance for the full year. It shows consistent growth.
Supportive ifQ2 2026 revenue reported at or above $21.1 million.
Worry ifQ2 2026 revenue falls below $20 million.
Why it matters: Stockholder approval is crucial for the merger. Without it, the merger cannot proceed, impacting future growth prospects.
Supportive ifStockholders will vote on the merger. A majority approval is needed.
Worry ifStockholder vote results in rejection of the merger.
Why it matters: Closing the merger is key for future growth and financial stability. It could provide over $900 million in cash.
Supportive ifThe merger closes by year-end 2026 with stockholder approval.
Worry ifThe merger fails to close by year-end 2026 due to stockholder or regulatory issues.